Cristina Sancricca, Massimiliano Mirabella, Carla Gliubizzi, Aldobrando Broccolini, Teresa Gidaro, Roberta Morosetti, Department of Neurosciences, Catholic University School of Medicine, Largo A. Gemelli 8, 00168 Rome, Italy.
World J Stem Cells. 2010 Jun 26;2(3):39-49. doi: 10.4252/wjsc.v2.i3.39.
Over the last years, the existence of different stem cells with myogenic potential has been widely investigated. Besides the classical skeletal muscle progenitors represented by satellite cells, numerous multipotent and embryologically unrelated progenitors with a potential role in muscle differentiation and repair have been identified. In order to conceive a therapeutic approach for degenerative muscle disorders, it is of primary importance to identify an ideal stem cell endowed with all the features for a possible use in vivo. Among all emerging populations, vessel-associated stem cells are a novel and promising class of multipotent progenitors of mesodermal origin and with high myogenic potential which seem to best fit all the requirements for a possible cell therapy. In vitro and in vivostudies have already tested the effectiveness and safety of vessel-associated stem cells in animal models. This leads to the concrete possibility in the future to start pilot human clinical trials, hopefully opening the way to a turning point in the treatment of genetic and acquired muscle disorders.
在过去的几年中,具有成肌潜能的不同干细胞的存在已经得到了广泛的研究。除了以卫星细胞为代表的经典骨骼肌祖细胞外,还发现了许多具有多能性且胚胎起源不同的祖细胞,它们在肌肉分化和修复中具有潜在作用。为了设想一种用于退行性肌肉疾病的治疗方法,首要的是鉴定一种具有所有特征的理想干细胞,以便可能在体内使用。在所有新兴群体中,血管相关干细胞是一类具有高成肌潜能的中胚层来源的新型有前途的多能祖细胞,它们似乎最符合所有可能的细胞治疗的要求。在体外和体内研究中已经在动物模型中测试了血管相关干细胞的有效性和安全性。这使得未来有具体的可能性开始进行人体临床试验,有望为治疗遗传和获得性肌肉疾病开辟新的途径。